155 related articles for article (PubMed ID: 25455448)
1. Evaluation of three physiologically based pharmacokinetic (PBPK) modeling tools for emergency risk assessment after acute dichloromethane exposure.
Boerleider RZ; Olie JD; van Eijkeren JC; Bos PM; Hof BG; de Vries I; Bessems JG; Meulenbelt J; Hunault CC
Toxicol Lett; 2015 Jan; 232(1):21-7. PubMed ID: 25455448
[TBL] [Abstract][Full Text] [Related]
2. Physiologically based pharmacokinetic modeling with dichloromethane, its metabolite, carbon monoxide, and blood carboxyhemoglobin in rats and humans.
Andersen ME; Clewell HJ; Gargas ML; MacNaughton MG; Reitz RH; Nolan RJ; McKenna MJ
Toxicol Appl Pharmacol; 1991 Mar; 108(1):14-27. PubMed ID: 1900959
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of two different metabolic hypotheses for dichloromethane toxicity using physiologically based pharmacokinetic modeling for in vivo inhalation gas uptake data exposure in female B6C3F1 mice.
Evans MV; Caldwell JC
Toxicol Appl Pharmacol; 2010 May; 244(3):280-90. PubMed ID: 20153349
[TBL] [Abstract][Full Text] [Related]
4. Revised assessment of cancer risk to dichloromethane: part I Bayesian PBPK and dose-response modeling in mice.
Marino DJ; Clewell HJ; Gentry PR; Covington TR; Hack CE; David RM; Morgott DA
Regul Toxicol Pharmacol; 2006 Jun; 45(1):44-54. PubMed ID: 16442684
[TBL] [Abstract][Full Text] [Related]
5. Probabilistic dose-response modeling: case study using dichloromethane PBPK model results.
Marino DJ; Starr TB
Regul Toxicol Pharmacol; 2007 Dec; 49(3):285-300. PubMed ID: 17949874
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of semi-generic PBTK modeling for emergency risk assessment after acute inhalation exposure to volatile hazardous chemicals.
Olie JD; Bessems JG; Clewell HJ; Meulenbelt J; Hunault CC
Chemosphere; 2015 Aug; 132():47-55. PubMed ID: 25794648
[TBL] [Abstract][Full Text] [Related]
7. Assessing the relevance of rodent data on chemical interactions for health risk assessment purposes: a case study with dichloromethane-toluene mixture.
Pelekis M; Krishnan K
Regul Toxicol Pharmacol; 1997 Feb; 25(1):79-86. PubMed ID: 9056503
[TBL] [Abstract][Full Text] [Related]
8. An approach for incorporating tissue composition data into physiologically based pharmacokinetic models.
Pelekis M; Poulin P; Krishnan K
Toxicol Ind Health; 1995; 11(5):511-22. PubMed ID: 8677516
[TBL] [Abstract][Full Text] [Related]
9. DNA-protein cross-links (DPX) and cell proliferation in B6C3F1 mice but not Syrian golden hamsters exposed to dichloromethane: pharmacokinetics and risk assessment with DPX as dosimeter.
Casanova M; Conolly RB; Heck H d'A
Fundam Appl Toxicol; 1996 May; 31(1):103-16. PubMed ID: 8998946
[TBL] [Abstract][Full Text] [Related]
10. Translational research to develop a human PBPK models tool kit-volatile organic compounds (VOCs).
Mumtaz MM; Ray M; Crowell SR; Keys D; Fisher J; Ruiz P
J Toxicol Environ Health A; 2012; 75(1):6-24. PubMed ID: 22047160
[TBL] [Abstract][Full Text] [Related]
11. Application of PBPK modeling in support of the derivation of toxicity reference values for 1,1,1-trichloroethane.
Lu Y; Rieth S; Lohitnavy M; Dennison J; El-Masri H; Barton HA; Bruckner J; Yang RS
Regul Toxicol Pharmacol; 2008 Mar; 50(2):249-60. PubMed ID: 18226845
[TBL] [Abstract][Full Text] [Related]
12. Effects of glutathione transferase theta polymorphism on the risk estimates of dichloromethane to humans.
El-Masri HA; Bell DA; Portier CJ
Toxicol Appl Pharmacol; 1999 Aug; 158(3):221-30. PubMed ID: 10438655
[TBL] [Abstract][Full Text] [Related]
13. Physiologically based pharmacokinetic modeling of inhalation exposure of humans to dichloromethane during moderate to heavy exercise.
Jonsson F; Bois F; Johanson G
Toxicol Sci; 2001 Feb; 59(2):209-18. PubMed ID: 11158713
[TBL] [Abstract][Full Text] [Related]
14. Combining transcriptomics and PBPK modeling indicates a primary role of hypoxia and altered circadian signaling in dichloromethane carcinogenicity in mouse lung and liver.
Andersen ME; Black MB; Campbell JL; Pendse SN; Clewell HJ; Pottenger LH; Bus JS; Dodd DE; Kemp DC; McMullen PD
Toxicol Appl Pharmacol; 2017 Oct; 332():149-158. PubMed ID: 28392392
[TBL] [Abstract][Full Text] [Related]
15. Assessing human variability in kinetics for exposures to multiple environmental chemicals: a physiologically based pharmacokinetic modeling case study with dichloromethane, benzene, toluene, ethylbenzene, and m-xylene.
Valcke M; Haddad S
J Toxicol Environ Health A; 2015; 78(7):409-31. PubMed ID: 25785556
[TBL] [Abstract][Full Text] [Related]
16. Application of physiologically based pharmacokinetic modeling in setting acute exposure guideline levels for methylene chloride.
Bos PM; Zeilmaker MJ; van Eijkeren JC
Toxicol Sci; 2006 Jun; 91(2):576-85. PubMed ID: 16569727
[TBL] [Abstract][Full Text] [Related]
17. Estimation of interindividual variation in oxidative metabolism of dichloromethane in human volunteers.
Sweeney LM; Kirman CR; Morgott DA; Gargas ML
Toxicol Lett; 2004 Dec; 154(3):201-16. PubMed ID: 15501612
[TBL] [Abstract][Full Text] [Related]
18. Revised assessment of cancer risk to dichloromethane II. Application of probabilistic methods to cancer risk determinations.
David RM; Clewell HJ; Gentry PR; Covington TR; Morgott DA; Marino DJ
Regul Toxicol Pharmacol; 2006 Jun; 45(1):55-65. PubMed ID: 16439044
[TBL] [Abstract][Full Text] [Related]
19. Use of in vitro data in developing a physiologically based pharmacokinetic model: Carbaryl as a case study.
Yoon M; Kedderis GL; Yan GZ; Clewell HJ
Toxicology; 2015 Jun; 332():52-66. PubMed ID: 24863738
[TBL] [Abstract][Full Text] [Related]
20. Workshop overview: reassessment of the cancer risk of dichloromethane in humans.
Starr TB; Matanoski G; Anders MW; Andersen ME
Toxicol Sci; 2006 May; 91(1):20-8. PubMed ID: 16507920
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
